Investigational drug · Phase 2
Berubicin
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Glioblastoma Multiforme, Adult.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "Berubicin"
First trial start
2021
May 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Berubicin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glioblastoma Multiforme, Adult
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Berubicin" as an intervention, largest first.
- A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma MultiformePivotal-lookingActive, not recruiting
CNS Pharmaceuticals, Inc.Industry
NCT04762069 · 252 participants · Start May 18, 2021 · Primary completion Apr 27, 2026
Drug: Berubicin; Lomustine · For: Glioblastoma Multiforme, Adult
Sites: Little Rock, Arkansas; Los Angeles, California; Orange, California · 48 sites in all
- RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain MetastasesTerminated
BiogenBiogen (BIIB)
NCT00538343 · 14 participants · Start Oct 31, 2007 · Primary completion Dec 1, 2008
Drug: berubicin hydrochloride (RTA 744) · For: Brain Metastases
Sites: West Palm Beach, Florida; Charlotte, North Carolina; Durham, North Carolina · 7 sites in all
WPD Pharmaceuticals Sp. z o.o.Industry
NCT04915404 · 5 participants · Start Dec 7, 2022 · Primary completion Dec 30, 2023
Drug: Berubicin Hydrochloride · For: Recurrent Glioblastoma Multiforme
Sites: Gdansk, Poland; Warsaw, Poland
WPD Pharmaceuticals Sp. z o.o.Industry
NCT05082493 · 0 participants · Start Dec 2023 · Primary completion Dec 30, 2023
Drug: Berubicin Hydrochloride · For: High Grade Glioma
Newest research
PubMed records naming it or its code names, newest first.
- Binding of Anthracyclines Within DNA-Topoisomerase ƏƏ Cleavage Complexes: Thermodynamics and Interactions.
Mikaelian G, Sarimveis H, Theodorou DN, et al. · J Chem Inf Model 2026
- Berubicin Substituted for Cytarabine in a MATRix-Based Regimen for Isolated Central Nervous System Lymphoma: A Five-Patient Case Series from the BER-PUM Study.
Milczarek S, Piotrowska O, Baumert B, et al. · Curr Oncol 2026
- Phase I trial and pharmacokinetic study of berubicin (RTA 744) in patients with recurrent or refractory high-grade gliomas.
Conrad CA, Hsu SH, Thapar N, et al. · Neurooncol Adv 2026
- Thermodynamics and Kinetics of the Deintercalation of a Novel Anthracycline from Double-Stranded Oligonucleotide DNA.
Mikaelian G, Sarimveis H, Theodorou DN, et al. · J Phys Chem B 2025
- Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess.
Ke H, Zhang Z, Yu Z, et al. · Front Pharmacol 2024
- Interactions of a Novel Anthracycline with Oligonucleotide DNA and Cyclodextrins in an Aqueous Environment.
Mikaelian G, Megariotis G, Theodorou DN · J Phys Chem B 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.